Avalo Therapeutics (AVTX) Long-Term Debt Repayments (2015 - 2023)
Avalo Therapeutics (AVTX) reported Long-Term Debt Repayments of $6.0 million for Q2 2023, down 60.0% on a YoY basis from $15.0 million in Q2 2022, and up 140.52% quarter-over-quarter from -$14.8 million in Q4 2022.
Avalo Therapeutics (AVTX) Long-Term Debt Repayments (2015 - 2023) Analysis & Trends
Avalo Therapeutics has reported Long-Term Debt Repayments for 6 years, with the latest figure at $6.0 million in Q2 2023.
- For the quarter ending Q2 2023, Long-Term Debt Repayments fell 60.0% year-over-year to $6.0 million; the trailing twelve-month figure through Dec 2024 stood at $6.0 million (down 3.13% YoY), and the FY2023 full-year result was $21.2 million, changed N/A from the prior year.
- Long-Term Debt Repayments for Q2 2023 stood at $6.0 million, up from -$14.8 million in the prior quarter.
- The five-year high for Long-Term Debt Repayments was $15.0 million in Q2 2022, with the low at -$14.8 million in Q4 2022.
- Historically, Long-Term Debt Repayments has averaged $921448.6 across 3 years, with a median of $24342.0 in 2019.
- The largest YoY upside for Long-Term Debt Repayments was 60.0% in 2023 against a maximum downside of 60.0% in 2023.
- Avalo Therapeutics' Long-Term Debt Repayments stood at $183114.0 in 2019, then slumped by 8185.67% to -$14.8 million in 2022, then jumped by 140.52% to $6.0 million in 2023.
- The last three Long-Term Debt Repayments figures came in at $6.0 million (Q2 2023), -$14.8 million (Q4 2022), and $15.0 million (Q2 2022), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Long-Term Debt Repayments (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | -21,671.00 |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | - |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | - |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | - |
| 10 | Avalo Therapeutics | 295.77 Mn | 295.77 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2023 | 6.00 Mn |
| Jun 30, 2023 | 6.00 Mn |
| Dec 31, 2022 | -14.81 Mn |
| Dec 31, 2022 | -14.81 Mn |
| Jun 30, 2022 | 15.00 Mn |
| Jun 30, 2022 | 15.00 Mn |
| Dec 31, 2019 | 183,114.00 |
| Dec 31, 2019 | 183,114.00 |
| Sep 30, 2019 | 24,342.00 |
| Sep 30, 2019 | 24,342.00 |
| Jun 30, 2019 | 24,342.00 |
| Jun 30, 2019 | 24,342.00 |
| Mar 31, 2019 | 24,342.00 |
| Mar 31, 2019 | 24,342.00 |
| Sep 30, 2017 | 606,610.00 |
| Sep 30, 2017 | 606,610.00 |
| Jun 30, 2017 | 892,721.00 |
| Jun 30, 2017 | 892,721.00 |
| Mar 31, 2017 | 874,700.00 |
| Mar 31, 2017 | 874,700.00 |